O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

被引:278
作者
Hermisson, M
Klumpp, A
Wick, W
Wischhusen, J
Nagel, G
Roos, W
Kaina, B
Weller, M
机构
[1] Univ Tubingen, Sch Med, Dept Gen Neurol, Lab Mol Neurooncol,Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany
[2] Univ Mainz, Inst Toxicol, D-6500 Mainz, Germany
关键词
BCL-XL; glioblastoma; O-6-methylguanine DNA methyltransferase; p53; temozolomide;
D O I
10.1111/j.1471-4159.2005.03583.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Temozolomide (TMZ) is a methylating agent which prolongs survival when administered during and after radiotherapy in the first-line treatment of glioblastoma and which also has significant activity in recurrent disease. O-6-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme attributed a role in cancer cell resistance to O-6-alkylating agent-based chemotherapy. Using a panel of 12 human glioma cell lines, we here defined the sensitivity to TMZ in acute cytotoxicity and clonogenic survival assays in relation to MGMT, mismatch repair and p53 status and its modulation by dexamethasone, irradiation and BCL-X-L. We found that the levels of MGMT expression were a major predictor of TMZ sensitivity in human glioma cells. MGMT activity and clonogenic survival after TMZ exposure are highly correlated (p < 0.0001, r(2) = 0.92). In contrast, clonogenic survival after TMZ exposure does not correlate with the expression levels of the mismatch repair proteins mutS homologue 2, mutS homologue 6 or post-meiotic segregation increased 2. The MGMT inhibitor O-6-benzylguanine sensitizes MGMT-positive glioma cells to TMZ whereas MGMT gene transfer into MGMT-negative cells confers protection. The antiapoptotic BCL-X-L protein attenuates TMZ cytotoxicity in MGMT-negative LNT-229 but not in MGMT-positive LN-18 cells. Neither ionizing radiation (4 Gy) nor clinically relevant concentrations of dexamethasone modulate MGMT activity or TMZ sensitivity. Abrogation of p53 wild-type function strongly attenuates TMZ cytotoxicity. Conversely, p53 mimetic agents designed to stabilize the wild-type conformation of p53 sensitize glioma cells for TMZ cytotoxicity. Collectively, these results suggest that the determination of MGMT expression and p53 status will help to identify glioma patients who will or will not respond to TMZ.
引用
收藏
页码:766 / 776
页数:11
相关论文
共 62 条
[1]  
Afra D, 2002, LANCET, V359, P1011
[2]  
[Anonymous], N ENGL J MED
[3]   DEPLETION OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE CORRELATES WITH POTENTIATION OF TEMOZOLOMIDE AND CCNU TOXICITY IN HUMAN TUMOR-CELLS [J].
BAER, JC ;
FREEMAN, AA ;
NEWLANDS, ES ;
WATSON, AJ ;
RAFFERTY, JA ;
MARGISON, GP .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1299-1302
[4]  
Barvaux VA, 2004, MOL CANCER THER, V3, P1215
[5]  
Barvaux VA, 2004, MOL CANCER THER, V3, P123
[6]   Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone [J].
Biswas, T ;
Ramana, CV ;
Srinivasan, G ;
Boldogh, I ;
Hazra, TK ;
Chen, ZP ;
Tano, K ;
Thompson, EB ;
Mitra, S .
ONCOGENE, 1999, 18 (02) :525-532
[7]  
Bocangel DB, 2002, CLIN CANCER RES, V8, P2725
[8]   BIOAVAILABILITY OF ORAL DEXAMETHASONE DURING HIGH-DOSE STEROID-THERAPY IN NEUROLOGICAL PATIENTS [J].
BROPHY, TRO ;
MCCAFFERTY, J ;
TYRER, JH ;
EADIE, MJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (01) :103-108
[9]   Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].
Bykov, VJN ;
Issaeva, N ;
Shilov, A ;
Hultcrantz, M ;
Pugacheva, E ;
Chumakov, P ;
Bergman, J ;
Wiman, KG ;
Selivanova, G .
NATURE MEDICINE, 2002, 8 (03) :282-288
[10]   Processing of O-6-methylguanine by mismatch correction in human cell extracts [J].
Ceccotti, S ;
Aquilina, G ;
Macpherson, P ;
Yamada, M ;
Karran, P ;
Bignami, M .
CURRENT BIOLOGY, 1996, 6 (11) :1528-1531